You are about to leave the Clinical Value website now.
Cancel
Continue
Liver Cancer
HCC Monitoring and Surveillance Update – The Limbic
Read ArticleHCC Monitoring and Surveillance Update – The Limbic
Known also as the silent killer, chronic liver disease is big, complex and accelerating. Driven by viral infection, diet and lifestyle, 1.5 billion people worldwide are in jeopardy. Of these, 80% of new cases and 72% of total deaths occur in Asia alone.
From disease understanding, diagnostic testing, therapeutic treatments to monitoring – a new era of partnership and innovation provides the opportunity to improve the lives of millions of people around the world.
Expert Opinions
27 June 2024
The implications of identifying and managing HCC surveillance patients in General Practice
9 December 2022
Liver Disease in Asia Pacific: Insights from Prof Pierce Chow
In this Q&A, Prof Pierce Chow of the National Cancer Centre Singapore discusses the epidemiology of liver disease in Asia Pacific; key considerations around the clinical…
READ MORE
9 December 2022
Liver Cancer in Japan: Dr Shun Kaneko on HCC Screening and Surveillance
Japan is a global leader in hepatocellular carcinoma (HCC) surveillance, with an effective programme that enables early-stage carcinomas detection. Yet unmet needs continue to affect the…
READ MORE
9 December 2022
Strengthening healthcare systems through the critical role of diagnostics
In line with the WHO Essential Diagnostics List (EDL) and Lancet Commission efforts, the Asia Pacific Medical Technology Association and its members recently came together to…
READ MOREKey Publications
2 October 2023
Patient-centric and ecosystem insights into hepatocellular carcinoma across Asia-Pacific – LEAP
In this white paper, insights on the liver ecosystem are uncovered, with the intention of facilitating action among various stakeholders to reduce liver cancer incidence and…
READ MORE
23 August 2023
Building modern hepatocellular carcinoma surveillance programmes: taking steps to address a leading cause of liver cancer death in Asia
In this whitepaper, HCC surveillance programs in Asia were analysed. The learnings from well established HCC surveillance programs, as well as the challenges in areas that…
READ MORE
14 March 2023
International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma
This white paper, which was developed by a group of experts in biomarker development, provides a framework on best practices to design, execute, and interpret biomarker…
READ MORE
9 December 2022
APACMed White Paper – Strengthening Healthcare Systems Through the Critical Role of Diagnostics
Diagnostic technologies are used across the entire patient journey of multiple disease states, and provide the tools to prevent, detect, and monitor the required interventions. Despite…
READ MOREWebinars and Symposiums
19 June 2024
Hepatocellular Carcinoma Surveillance: Challenging the status quo
Disease Awareness
30 May 2024
Unravelling the enigma: Metabolic associated fatty liver disease (MAFLD) and liver cancer
29 May 2024
Who should be tested for liver cancer and why is testing so important?
27 May 2024
Liver cancer surveillance: what’s stopping my patients getting tested?
26 February 2024
Looking to the Future – Blood-based Biomarkers for Liver Cancer Surveillance
